SCHEMBL3537014

SCHEMBL3537014

CC1CCN(c2nc(N3CCN(CC(=O)N4CCOCC4)CC3)ccc2[N+](=O)[O-])CC1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.48
TDP1 Q9NUW8 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 6/20 0.47
MAPK1 P28482 3/20 0.47
POLB P06746 1/20 0.47
KDM4E B2RXH2 2/20 0.47
RECQL P46063 1/20 0.47
NPSR1 Q6W5P4 2/20 0.42
LMNA P02545 2/20 0.41
MEN1 O00255 2/20 0.41
GPR174 Q9BXC1 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 1/20 0.41
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3539286 0.96 TDP1 (0.53) MAPTTDP1KMT2AALDH1A1MAPK1
SCHEMBL3539569 0.91 MAPT (0.46) MAPTTDP1KMT2AALDH1A1MAPK1
SCHEMBL3534730 0.85 ALDH1A1 (0.50) MAPTTDP1KMT2AALDH1A1POLB
SCHEMBL3536204 0.82 MAPT (0.53) MAPTTDP1KMT2AALDH1A1MAPK1
SCHEMBL5188971 0.82 ALDH1A1 (0.55) MAPTTDP1KMT2AALDH1A1KDM4E
SCHEMBL3540736 0.81 ALDH1A1 (0.55) MAPTTDP1KMT2AALDH1A1MAPK1
SCHEMBL3539291 0.78 MAPT (0.63) MAPTTDP1KMT2AALDH1A1MAPK1
Trifluoroacetic Acid SCHEMBL3542661 0.76 ALDH1A1 (0.49) MAPTTDP1KMT2AALDH1A1MAPK1
SCHEMBL13405755 0.74 MAPT (0.61) MAPTTDP1KMT2AALDH1A1MAPK1
SCHEMBL13405754 0.74 CSF1R (0.72) ALDH1A1KDM4ERECQLGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES MAPT 159/4885TDP1 2371/4885KMT2A 911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.